39 reports

  • Schizophrenia and Psychotic Disorders
  • 2.2.1 PSYCHOTIC DISORDER: DEFINITION

Eating Disorders ##. ##. ## PSYCHOTIC DISORDER: DEFINITION ##. ## Psychotic Disorder: An Overview Psychotic disorders are a group of serious illnesses that affect the mind.

  • Psychotic Disorder
  • Alkermes plc
  • Eli Lilly & Co.
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • CPL-50003602 - Drug Profile
  • Phase II - Trial Details

Researchers identified ##-[##-fluoro-##-(##H-pyrazol-##-yl)phenyl]-##-methoxy-##-(##-phenyl-##H-pyrazol-##yl)pyridazin-##(##H)-one (##h).

  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • World
  • Product Initiative
  • CPL-50003602 - Drug Profile
  • PHASE II - TRIAL DETAILS

Researchers identified ##-[##-fluoro-##-(##H-pyrazol-##-yl)phenyl]-##-methoxy-##-(##-phenyl-##H-pyrazol-##yl)pyridazin-##(##H)-one (##h).

  • Hospital
  • Pharmaceutical
  • Psychotic Disorder
  • World
  • Product Initiative

Its products are indicated for the treatment of diseases such as Alzheimer' s disease, depression, Parkinson' s disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntington' s disease, among others.

  • Psychotic Disorder
  • Therapy
  • United States
  • Company Financials
  • Acorda Therapeutics, Inc.
  • Target
  • 5. All the trials included are unique trials.

SCHIZOAFFECTIVE DISORDER THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* SCHIZOAFFECTIVE DISORDER THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* Country Name Phase IV Phase III/ IV Phase III Phase II/ III Phase II Phase I/ II Phase I Phase ## Tot

  • Clinical Trial
  • Neurology
  • Psychotic Disorder
  • World
  • Product Initiative

Patients are randomized ##:## to placebo or SYN## dosed once daily over a ## week treatment period.

  • Psychotic Disorder
  • Therapy
  • United States
  • Company
  • Biotie Therapies Corp.
  • CPL-50003602 - Drug Profile

Researchers identified ##-[##-fluoro-##-(##H-pyrazol-##-yl)phenyl]-##-methoxy-##-(##-phenyl-##H-pyrazol-##yl)pyridazin-##(##H)-one (##h).

  • Hospital
  • Pharmaceutical
  • Psychotic Disorder
  • World
  • Product Initiative
  • SMALL MOLECULES TO INHIBIT VMAT-2 FOR BIPOLAR DISORDER, MOVEMENT DISORDERS AND SCHIZOPHRENIA - DRUG PROFILE
  • FEATURED NEWS & PRESS RELEASES

The most common were worsening of schizophrenia (##. ##%) and psychotic disorder (##. ##%).

  • Pharmaceutical
  • Psychotic Disorder
  • United States
  • Company
  • Product Initiative

The psychiatric diagnoses included primarily depressive, bipolar, anxiety and psychotic disorders.

  • Psychotic Disorder
  • Therapy
  • World
  • Product Initiative
  • Suven Life Sciences Ltd

The psychiatric diagnoses included primarily depressive, bipolar, anxiety and psychotic disorders.

  • Psychotic Disorder
  • Therapy
  • World
  • Product Initiative
  • Suven Life Sciences Ltd
  • AUG 25, 2016: THE LARGEST AND LONGEST STUDY OF PATIENTS WITH SCHIZOPHRENIA INTERACTING WITH DIGITAL THERAPEUTICS RESULTS RELEASED

The study evaluated ## participants between ##-## years of age, who had been diagnosed with a psychotic disorder and were discharged from a psychiatric hospitalization within ## days.

  • Clinical Trial
  • Psychotic Disorder
  • Therapy
  • United States
  • Product Initiative
  • Clinical Trial profile. 274 Trial Title
  • Clinical Trial profile. 171 Trial Title

## ## ## ## ## ## ## ## China ## ## ## ## ## ## ## ## Russia ## ## ## ## ## ## ## ## Brazil ## ## ## ## ## ## ## ## Mexico ## ## ## ## ## ## ## ## Turkey Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are ta

  • Antipsychotic
  • Clinical Trial
  • Psychotic Disorder
  • Therapy
  • World
  • SERX-480 - DRUG PROFILE

RP## is also under development for the treatment of brain disorders such as from major depressive disorder (MDD), manic-depressive bipolar disorder, psychosis in Parkinson' s and Alzheimer' s diseases, Tourette' s syndrome, autism and attention defic

  • Pharmaceutical
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Reviva Pharmaceuticals Inc.

The disorder can be BIPOLAR DISORDER divided into two types: bipolar disorder type I, characterized by at least one episode of mania with or without a depressive episode, whereas the bipolar disorder type II is characterized by at least one hypom

  • Psychotic Disorder
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • SMALL MOLECULES TO INHIBIT VMAT-2 FOR BIPOLAR DISORDER, MOVEMENT DISORDERS AND SCHIZOPHRENIA - DRUG PROFILE
  • Licensing and Collaboration

Approximately one-third of patients in the study had more severe psychotic symptoms (NPI-NH Psychosis score equal to ##).

  • Mental Health
  • Psychotic Disorder
  • United States
  • Company
  • Omeros Corporation
  • R&D Progress Research and Development Brief

The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ## and ## respectively.

  • Psychotic Disorder
  • United States
  • World
  • Product Initiative
  • Reviva Pharmaceuticals Inc.
  • lurasidone hydrochloride - Drug Profile

Adverse events associated with SEROQUEL XR (greater than or equal to ##%) included schizophrenia, headache, insomnia, psychotic disorder, increased weight and agitation.

  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • United States
  • Product Initiative

The psychiatric diagnoses included primarily depressive, bipolar, anxiety and psychotic disorders.

  • OTC
  • Psychotic Disorder
  • Smoking Cessation
  • United States
  • Product Initiative

The psychiatric diagnoses included primarily depressive, bipolar, anxiety and psychotic disorders.

  • Psychotic Disorder
  • Smoking Cessation
  • United States
  • Product Initiative
  • Suven Life Sciences Ltd
  • CPL-50003602 - DRUG PROFILE

Researchers identified ##-[##-fluoro-##-(##H-pyrazol-##-yl)phenyl]-##-methoxy-##-(##-phenyl-##H-pyrazol-##yl)pyridazin-##(##H)-one (##h).

  • Antimalarials
  • Psychotic Disorder
  • United States
  • World
  • Pfizer Inc.
  • 2.4 FORECAST METHODOLOGY
  • 2.2 RISK FACTORS AND COMORBIDITIES

The authors used an ICD-## definition of psychotic disorders.

  • Psychotic Disorder
  • Japan
  • United Kingdom
  • United States
  • Forecast
  • Apr 25, 2018: How the brain is folded provides researchers with an accurate marker to predict psychosis in high-risk patients
  • Mar 05, 2018: Early psychosis programs significantly reduce patient mortality, study finds

The researchers point out that approximately ## in ## young people experience psychosis-risk symptoms, but only one per cent will develop long-standing psychotic disorders such as schizophrenia.

  • Healthcare
  • Psychotic Disorder
  • Canada
  • Company
  • Deals & Alliance
  • Apr 25, 2018: How the brain is folded provides researchers with an accurate marker to predict psychosis in high-risk patients
  • Mar 05, 2018: Early psychosis programs significantly reduce patient mortality, study finds

The researchers point out that approximately ## in ## young people experience psychosis-risk symptoms, but only one per cent will develop long-standing psychotic disorders such as schizophrenia.

  • Healthcare
  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • Canada

The number of people suffering from psychotic disorders is also rising in India.

  • Psychotic Disorder
  • North America
  • United States
  • World
  • Market Size

STUDY DESIGN Aripiprazole is an atypical antipsychotic and the active ingredient in Abilify®, a leading medication in the US used for the treatment of a number of psychiatric disorders including bipolar I disorder, schizophrenia, major depressive disorder and irri

  • Clinical Trial
  • Psychotic Disorder
  • United States
  • Company
  • Aequus Pharmaceuticals Inc.
  • SMALL MOLECULE TO INHIBIT VMAT-2 FOR BIPOLAR DISORDER, MOVEMENT DISORDERS AND SCHIZOPHRENIA - DRUG PROFILE

Its areas of interest include Autism Spectrum Disorder, Bipolar I disorder and schizophrenia.

  • Psychotic Disorder
  • Therapy
  • United States
  • Product Initiative
  • Intra-Cellular Therapies, Inc.
  • Stages of the course of schizophrenia
  • REFERENCES

Lifetime prevalence of psychotic and bipolar I disorders in a general population.

  • Mental Health
  • Pathology
  • Psychotic Disorder
  • Northern Europe
  • Western Europe

In Study ##B: Patients were randomized to one of three treatment groups (brexanolone ## mcg/ kg/ hour, brexanolone ## mcg/ kg/ hour, or placebo) on a ##:##:## basis.

  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • United States
  • Product Initiative
  • 4.4 FORECAST METHODOLOGY
  • and Figure 2 present the number of 12-month diagnosed prevalent cases of schizophrenia

Treatment of acute agitation in psychotic disorders.

  • Psychotic Disorder
  • Alkermes plc
  • Janssen Biotech, Inc.
  • Lundbeck Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Schizophrenia, Global, Key Features of Tau Protein
  • Schizophrenia, Global, Evidence for Tau Protein (MAPT) as a Therapeutic Target, 2018

The signal transducer protein reelin has been implicated in psychotic disorders including schizophrenia.

  • Mental Health
  • Pathology
  • Psychotic Disorder
  • Therapy
  • Deals & Alliance